Blood lymphocyte proliferation response to pollen extract as a monitor of immunotherapy.
In a study of immunotherapy 41 children with seasonal rhinoconjunctivitis due to deciduous tree pollen allergy were monitored by means of symptom scoring, patient self-evaluation, conjunctival provocation tests and lymphocyte proliferation in vitro to the allergen. The lymphocyte responsiveness to birch pollen decreased significantly during the first year of immunotherapy. However, neither the lymphocyte responsiveness before treatment nor changes in lymphocyte reactivity during the immunotherapy correlated with the clinical efficacy of the therapy as evaluated by changes in symptom scores, self-evaluation or conjunctival provocation test changes in the individual patients. The results indicate that lymphocyte responsiveness to an allergen cannot be used to select patients for immunotherapy, i.e. to predict whether a patient would benefit from immunotherapy or not, or to evaluate the effects of immunotherapy after beginning the treatment. However, lymphocyte proliferation response to an allergen indicates clinical sensitivity.
D000293:Adolescent; D002648:Child; D003228:Conjunctiva / Q000276:immunology; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use; D011058:Pollen; D011379:Prognosis; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood / Q000276:immunology / Q000628:therapy*
D010936:Plant Extracts